MLT 106.8 REGULATORY REQUIREMENTS
AND MANAGEMENT IN BLOOD BANK 2026
VERSION | COMPREHENSIVE PRACTICE
QUESTIONS & VERIFIED CORRECT
ANSWERS | BLOOD BANK REGULATIONS,
QUALITY ASSURANCE, BLOOD
TRANSFUSION SERVICES,
ACCREDITATION & LABORATORY
MANAGEMENT STUDY GUIDE | GRADE A+
Moderate potential to have an adverse effect on the safety and effectivity of
products - CORRECT ANSWER -Moderate change
With substantial potential to have an adverse effect on the safety or
effectiveness of the product - CORRECT ANSWER -Major change
Regulations specific for blood and blood components are found - CORRECT
ANSWER -Title 21 CFR part 606 (known as cGMP regulation)
cGMP includes the following elements - CORRECT ANSWER -Quality
assurance
Quality control
Process validation
, Deviations from cGMP or unexpected events in a manufacturing operation
adversely affect - CORRECT ANSWER -The safety, purity, or potency of
biological blood and blood components
Incorporated into blood manufacturers SOP's to perform procedures that
vary from what is required and approved by the CBER director - CORRECT
ANSWER -Alternative procedures
Arrangement of the partial manufacture of a biological product of an
unlicensed facility under controlled conditions - CORRECT ANSWER -Short
supply arrangements
Classified as Class 1, 2, or 3 based on the potential for product to cause
serious health problems - CORRECT ANSWER -Product recalls
Fatality reporting is - CORRECT ANSWER -Formal notification of CBER
within seven days after a patient fatality is confirmed due to transfusion
related fatalities or donor related deaths
Commitment of blood donor centers, hospital, blood banks, and
transfusion services in embracing quality philosophy is - CORRECT
ANSWER -To ensure a high degree of safe blood donation and transfusion
practices
Things built into a product - CORRECT ANSWER -Quality
Safety
AND MANAGEMENT IN BLOOD BANK 2026
VERSION | COMPREHENSIVE PRACTICE
QUESTIONS & VERIFIED CORRECT
ANSWERS | BLOOD BANK REGULATIONS,
QUALITY ASSURANCE, BLOOD
TRANSFUSION SERVICES,
ACCREDITATION & LABORATORY
MANAGEMENT STUDY GUIDE | GRADE A+
Moderate potential to have an adverse effect on the safety and effectivity of
products - CORRECT ANSWER -Moderate change
With substantial potential to have an adverse effect on the safety or
effectiveness of the product - CORRECT ANSWER -Major change
Regulations specific for blood and blood components are found - CORRECT
ANSWER -Title 21 CFR part 606 (known as cGMP regulation)
cGMP includes the following elements - CORRECT ANSWER -Quality
assurance
Quality control
Process validation
, Deviations from cGMP or unexpected events in a manufacturing operation
adversely affect - CORRECT ANSWER -The safety, purity, or potency of
biological blood and blood components
Incorporated into blood manufacturers SOP's to perform procedures that
vary from what is required and approved by the CBER director - CORRECT
ANSWER -Alternative procedures
Arrangement of the partial manufacture of a biological product of an
unlicensed facility under controlled conditions - CORRECT ANSWER -Short
supply arrangements
Classified as Class 1, 2, or 3 based on the potential for product to cause
serious health problems - CORRECT ANSWER -Product recalls
Fatality reporting is - CORRECT ANSWER -Formal notification of CBER
within seven days after a patient fatality is confirmed due to transfusion
related fatalities or donor related deaths
Commitment of blood donor centers, hospital, blood banks, and
transfusion services in embracing quality philosophy is - CORRECT
ANSWER -To ensure a high degree of safe blood donation and transfusion
practices
Things built into a product - CORRECT ANSWER -Quality
Safety
